Neurosense TherapeuticsNRSN
13F holders, Q4 2025 (December 31)13holders +3
5new positions
2sold out
$0.77avg. 13F price*
At the end of Q4 2025, 13 institutions reported holding Neurosense Therapeutics Ltd. (NRSN) in their 13F filings, up 3 from Q3 2025. 5 opened new positions and 2 sold out. The largest holders were Yorkville Advisors Global, LP ($77K), Two Sigma Investments, LP ($40K) and Meitav Investment House Ltd. ($31K).
- Company
- Neurosense Therapeutics Ltd.
- CUSIP
- M74240108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $127K |
| Exits | 2 | $84K |
All 13F filers, Q3 2025 → Q4 2025: 213,058 shares bought and 144,849 shares sold, net +68,209 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Yorkville Advisors Global, LP | 0.05% | New | 100,000 | $77K |
| Two Sigma Investments, LP | 0.00% | Add +144.4% | 51,545 | $40K |
| Meitav Investment House Ltd. | 0.00% | No change | 40,000 | $31K |
| GTS Securities LLC | 0.00% | New | 35,753 | $27K |
| UBS Group AG | 0.00% | Add +110.6% | 30,871 | $24K |
| Commonwealth Equity Services, LLC | 0.00% | Add +8.0% | 22,775 | $18K |
| Squarepoint Ops LLC | 0.00% | Reduce -81.2% | 17,926 | $14K |
| Pathstone Holdings, LLC | 0.00% | New | 16,528 | $13K |
| Geode Capital Management, LLC | 0.00% | No change | 15,870 | $12K |
| Creative Planning | 0.00% | New | 11,911 | $9K |
| SBI Securities Co., Ltd. | 0.00% | No change | 1,455 | $1K |
| Jones Financial Companies LLLP | 0.00% | No change | 1,000 | $769 |
| Jessup Wealth Management, Inc | 0.00% | New | 500 | $385 |
"% of holder's portfolio" is NRSN's weight in each manager's 13F, not the share of Neurosense Therapeutics Ltd. the manager owns.